# Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

> **NCT01453101** · PHASE2 · COMPLETED · sponsor: **Hackensack Meridian Health** · enrollment: 54 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Fludarabine monophosphate, melphalan, Bortezomib

## Key facts

- **NCT ID:** NCT01453101
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-09
- **Primary completion:** 2020-06-11
- **Final completion:** 2020-06-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453101, "Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01453101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*